August 1, 2023
Brandi Reeves, MD, received a 5-year NHLBI K08 Mentored Clinical Scientist Development Award for a research project evaluating the role of hypoxia inducible factor in myeloproliferative-associated thrombosis. These awards are judged not only on the merit of the candidate, training plan, and the research proposal, but also on institutional environment and mentoring team. Her mentoring …
June 20, 2023
BRC Abstracts for ISTH Montreal 2023
April 1, 2023
Click here to read the April 2023 Newsletter
March 31, 2023
Hemostatic plug formation at sites of vascular injury is strongly dependent on rapid platelet activation and aggregation. However, to prevent thrombotic complications, platelet aggregate formation is regulated, in part, by the desensitization of the platelet P2Y1 receptor. Here, we analyzed a novel knock-in mouse strain expressing a P2Y1 receptor variant that cannot be desensitized. The …
March 27, 2023
Steven Grover, PhD was invited to present on the role of C1 inhibitor in venous thrombosis at the inaugural Immunothrombosis Symposium held at the Center for Advanced Studies of Ludwig Maximilians Universität in Munich. The two day symposium, hosted by Drs Konstantin Stark and Leo Nicolai, brought together researchers with an interest in immunothrombotic pathologies to …
March 26, 2023
Raj Kasthuri, MD co-authored a publication in the Annals of Internal Medicine titled Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. Patients hospitalized with COVID-19 have an increased incidence of thromboembolism. The role of extended thromboprophylaxis after hospital discharge is unclear. To determine whether anticoagulation is superior to placebo in reducing death and …
March 17, 2023
Drs. Mackman and Hisada published an invited review article entitled “Mechanisms of cancer-associated thrombosis” in Research and Practice in Thrombosis and Haemostasis. In the review, they described 4 pathways of cancer-associated thrombosis including tissue factor-positive extracellular vesicles, podoplanin, neutrophil extracellular traps and plasminogen activator inhibitor-1. This review article is based on a State-of-the-Art lecture presented …
March 16, 2023
Erica Sparkenbaugh, PhD was awarded a one-year Stage 1 SBIR grant from NHLBI (HL169107-01) titled Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease. She is a subcontract on the grant with Chris Dockendorff at Function Therapeutics as PI.
March 14, 2023
Yasmina Abajas’, MD paper ‘Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children’s Hospital Acquired Thrombosis (CHAT) Consortium’ was published in the Research and Practice in Thrombosis and Haemostasis journal. Click here to read the paper.
February 23, 2023
The results of 2 phase 3 trials of AAV-mediated gene therapy for hemophilia A and hemophilia B were published back-to-back in the New England Journal of Medicine on February 23, 2023. Dr. Nigel Key was a collaborator and co-author on both studies, each of which included patients from UNC. The hemophilia A study (Biomarin Pharmacuticals) …
February 23, 2023
Sickle cell disease carries a significant risk of venous thrombosis, yet evidence suggests that anti-coagulant therapy increases the risk of bleeding in individuals with SCD. Coagulation FXII, which contributes to thrombosis but not hemostasis, is an appealing target for treating thrombosis without carrying a bleeding risk. Work led by Erica Sparkenbaugh and Rafal Pawlinski demonstrates …
February 22, 2023
Dr. Callie Berkowitz, a second year hematology fellow, has been selected for the Promoting XXcellence in Women’s Health: Optimal Management of Women and Girls with Bleeding Disorders special research award from the Foundation for Women and Girls with Blood Disorders. Her project will explore hemostatic outcomes and patients needs in women with bleeding of unknown …